Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It’s essential for these enterprises to show tangible outcomes rather than relying solely on marketing strategies. Simo identifies biological data as a critical hurdle in developing AI-based treatments, particularly noting that cancer research benefits from vast pre-existing datasets. Establishing the needed infrastructure is vital for translating AI intelligence into effective medical solutions. Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It’s essential for these enterprises to show tangible outcomes rather than relying solely on marketing strategies. Simo identifies biological data as a critical hurdle in developing AI-based treatments, particularly noting that cancer research benefits from vast pre-existing datasets. Establishing the needed infrastructure is vital for translating AI intelligence into effective medical solutions.
Trending
- David Warner convicted of drink-driving; Big Bash captaincy under cloud
- Canadian mom gets a keyboard tattooed on her arm so her autistic son can ‘talk’
- Henrietta Lacks died at 31, but her cells lived on and transformed modern medicine
- Webb’s ‘little red dots’ puzzled astronomers; this galaxy may hold the answer
- US mother sues Portland Public School after being barred from campus following gender policy dispute
- Russia warns UK over Ukraine drone supplies, says Britain will face ‘consequences’
- Why India is considering sugar imports as prices hit record levels
- Cyprus grape helps Australian vineyards cope with extreme heat and use less water
OpenAI’s former exec disagrees with Amodei on most things, but backs his AI cancer view
By
Add A Comment